{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:53:34Z","timestamp":1761486814002},"reference-count":20,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2001,11,1]],"date-time":"2001-11-01T00:00:00Z","timestamp":1004572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2001,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            BMS-284756 is a novel des-fluoro(6) quinolone with a broad antimicrobial activity, including\n            <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n            . The purpose of this study was to evaluate the pharmacodynamic profile and effectiveness of BMS-284756 for therapy of experimental meningitis caused by penicillin- and cephalosporin-resistant\n            <jats:italic>S. pneumoniae<\/jats:italic>\n            (CRSP). Meningitis was induced in rabbits by intracisternal inoculation of CRSP. BMS-284756 was given intravenously 16 h after intracisternal inoculation in single doses of 2.5 (\n            <jats:italic>n<\/jats:italic>\n            = 5 animals), 5 (\n            <jats:italic>n<\/jats:italic>\n            = 6), 10 (\n            <jats:italic>n<\/jats:italic>\n            = 6), 20 (\n            <jats:italic>n<\/jats:italic>\n            = 8), and 30 mg\/kg (\n            <jats:italic>n<\/jats:italic>\n            = 6), in two doses of 10 mg\/kg each separated by 5 h (\n            <jats:italic>n<\/jats:italic>\n            = 4), and as a 20-mg\/kg dose followed 5 h later by 10 mg\/kg (\n            <jats:italic>n<\/jats:italic>\n            = 5). The MICs and MBCs of BMS-284756, ceftriaxone, and vancomycin were 0.06 and 0.06, 4 and 4, and 0.25 and 0.25 \u03bcg\/ml, respectively. After single doses of 10, 20, and 30 mg\/kg, the maximum concentrations in cerebrospinal fluid (CSF) (mean \u00b1 standard deviation) were 0.32 \u00b1 0.12, 0.81 \u00b1 0.38, and 1.08 \u00b1 0.43 \u03bcg\/ml, respectively; the elimination half-life in CSF was 4.5 to 6.3 h. The CSF bacterial killing rates (BKR) at 5 h of the single-dose regimens of 10, 20 and 30 mg\/kg were \u22120.84 \u00b1 0.48, \u22121.09 \u00b1 0.32, and \u22121.35 \u00b1 0.05 \u0394log\n            <jats:sub>10<\/jats:sub>\n            CFU\/ml\/h. The BKR\n            <jats:sub>0\u20135<\/jats:sub>\n            of the divided regimens (10 mg\/kg twice and 20 mg\/kg followed by 10 mg\/kg) was \u22120.82 \u00b1 0.52 and \u22121.24 \u00b1 0.34 \u0394log\n            <jats:sub>10<\/jats:sub>\n            CFU\/ml\/h, respectively. The BKR\n            <jats:sub>0\u20135<\/jats:sub>\n            of the combined therapy with vancomycin and ceftriaxone was \u22121.09 \u00b1 0.39 \u0394log\n            <jats:sub>10<\/jats:sub>\n            CFU\/ml\/h. The penetration of BMS-284756 into purulent CSF relative to plasma was 14 to 25%. The bactericidal effect of BMS-284756 in CSF was concentration dependent. BMS-284756 at 30 mg\/kg as a single or divided dose was as effective as standard therapy with vancomycin and ceftriaxone.\n          <\/jats:p>","DOI":"10.1128\/aac.45.11.3098-3103.2001","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"3098-3103","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":17,"title":["BMS-284756 in Experimental Cephalosporin-Resistant Pneumococcal Meningitis"],"prefix":"10.1128","volume":"45","author":[{"given":"Violeta","family":"Rodriguez-Cerrato","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faryal","family":"Ghaffar","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus","family":"Saavedra","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian C.","family":"Michelow","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D.","family":"Hardy","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janie","family":"Iglehart","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Olsen","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"George H.","family":"McCracken","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.102.5.1087"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.6.4.437"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/313606"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199303000-00004"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.12.3351-3356.2000"},{"key":"e_1_3_2_8_2","unstructured":"Gabrielsson\n              J.\n              Weiner\n              D.\n          Non-compartmental analysis\n          Pharmacokinetic and pharmacodynamic data analysis: concepts and applications\n          2nd ed.\n              Gabrielsson\n              J.\n              Weiner\n              D.\n          1997\n          139\n          144\n          Swedish Pharmaceutical Press\n          Stockholm Sweden"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.6.1390"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.10.2650"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.5.683"},{"key":"e_1_3_2_12_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS publication no. M7\u2013A5. A3.\n          2000\n          National Committee for Clinical Laboratory Standards\n          Villanova Pa"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.6.1243"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.4.963"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110785"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.6.1397"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710023371404"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/am.19.4.573-579.1970"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI107767"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1077"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/514622"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.11.3098-3103.2001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.11.3098-3103.2001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:54:21Z","timestamp":1645462461000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.45.11.3098-3103.2001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["10.1128\/AAC.45.11.3098-3103.2001"],"URL":"https:\/\/doi.org\/10.1128\/aac.45.11.3098-3103.2001","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,11]]},"assertion":[{"value":"2001-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-07-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}